Novel Nanoparticle Targeting of Antimicrobials to Infected Diabetic Foot Ulcers

Collaborative feasibility study between three partners based in the West Midlands; Malvern Cosmeceutics Limited, the School of Biology, Chemistry & Forensic Science and the School of Biomedical Science and Physiology both at University of Wolverhampton together with clinical oversight from New Cross Hospital Wolverhampton, focussed on applying MCL’s proprietary nanoparticle delivery system, Lipodisq®, for topical treatment of infected diabetic foot ulcers (DFUs). Particular attention will be placed on improved targeting of existing approved drugs to Gram(-) bacteria especially those likely to develop multi-drug resistance (MDR) and implicated as the causative organisms in the development of severe and recurrent cases of DFUs, treatment of which currently consumes approx 1% of the NHS budget (£662 Million per annum). The commercial objective is to develop a high value, topical pharma product, future-proofed to overcome evolving bacterial resistance mechanisms, suitable for clinical trial, local manufacture and global distribution either directly by MCL or in partnership with UK-based wound care companies.